Eli Lilly is cutting insulin prices and capping copays at $35 – 5 questions answered
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)
Dana Goldman, University of Southern California and Karen Van Nuys, University of Southern California
(THE CONVERSATION) Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70% and capping insulin copays at US$35 for uninsured patients and those with private health insurance. These changes follow efforts by the federal government, the California state government, nonprofits and some companies to make insulin more affordable for the more than 7 million Americans with diabetes who require it.
The Conversation asked Dana...